Analyst Price Targets — AVLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 26, 2026 12:41 pm | Gavin Clark-Gartner | Evercore ISI | $51.00 | $28.41 | TheFly | Avalyn Pharma initiated with an Outperform at Evercore ISI |
| May 26, 2026 9:15 am | — | Morgan Stanley | $53.00 | $28.84 | TheFly | Avalyn Pharma initiated with an Overweight at Morgan Stanley |
| May 25, 2026 11:01 am | — | Jefferies | $52.00 | $28.84 | TheFly | Avalyn Pharma initiated with a Buy at Jefferies |
| May 25, 2026 10:42 am | — | Guggenheim | $80.00 | $28.84 | TheFly | Avalyn Pharma initiated with a Buy at Guggenheim |
Latest News for AVLN
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will present a company overview at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 9:55-10:25 a.m. ET.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026, being held June 3-6, 2026, in London, England. Updated findings from the…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for AVLN.
Senate Trading
No Senate trades found for AVLN.
U.S. House Trading
No House trades found for AVLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.